Additional molecularly targetable biomarker discoveries include BRAF mutation testing for variable tumors like melanoma and craniopharyngioma and anaplastic lymphoma kinase (ALK) inhibitors and epidermal growth factor receptors in various subtypes of lung cancer [32, 33]. Here, ALK is linked to lung carcinoma.